Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
BETHLEHEM, Pa., Feb. 24, 2017 -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Roger L. Pringle will be retiring as a member of the Company’s Board of Directors, effective May 16, 2017. Mr. Pringle is the Company’s longest tenured Director, having served on the Board since September 2000. Prior to that, Mr. Pringle served as Chairman of the Board and Director of one of the Company’s predecessors, Epitope, Inc. Mr. Pringle has also served as a member of both the Compensation and Audit Committees and previously as Chairman of the Compensation Committee.
“On behalf of the Company and my fellow Directors, I would like to express my deepest appreciation to Roger for his dedicated service to the Company and the Board of Directors,” said Dr. Stephen Tang, Chairman of OraSure’s Board of Directors. “During Roger’s tenure, there have been many significant changes at OraSure and the Company has grown substantially. His steadfast commitment and leadership have contributed to our success over these many years. Roger will be greatly missed and we wish him and his family nothing but good health and success for the future.”
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.
For more information on OraSure Technologies, please visit www.orasure.com.
Company contact: Ronald H. Spair Chief Financial Officer 610-882-1820 [email protected] www.orasure.com
